Cargando…

LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion

BACKGROUND: Targeting EBV-proteins with mRNA vaccines is a promising way to treat EBV-related tumors like nasopharyngeal carcinoma (NPC). We assume that it may sensitize tumors to immune checkpoint inhibitors. RESULTS: We developed an LMP2-mRNA lipid nanoparticle (C2@mLMP2) that can be delivered to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Yu, Tian, Miaomiao, Huang, Juan, Li, Yueyi, Li, Guangqi, Li, Xue, Jiang, Zedong, Song, Xiangrong, Ma, Xuelei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486025/ https://www.ncbi.nlm.nih.gov/pubmed/37679769 http://dx.doi.org/10.1186/s12951-023-02069-w

Ejemplares similares

Generating CTLs against the subdominant EBV LMP antigens by transit expression of an A20 inhibitor with EBV LMP proteins in human DCs
por: Hong, Bangxing, et al.
Publicado: (2011)

New Look of EBV LMP1 Signaling Landscape
por: Wang, Ling, et al.
Publicado: (2021)

A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma
por: Guo, Mengran, et al.
Publicado: (2023)

Measurement of CD8(+) and CD4(+) T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs
por: Sohn, Dae-Hee, et al.
Publicado: (2015)

Differential expression of EBV proteins LMP1 and BHFR1 in EBV-associated gastric and nasopharyngeal cancer tissues
por: WANG, AILIANG, et al.
Publicado: (2016)

The Anti-Apoptotic Role of EBV-LMP1 in Lymphoma Cells
por: Zeng, Mei, et al.
Publicado: (2020)

HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer
por: Lifang, Yang, et al.
Publicado: (2008)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis
por: ÖZDEMİR, Süleyman, et al.
Publicado: (2022)

Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma
por: Kamara, Saidu, et al.
Publicado: (2023)

EBV‐LMP1 induces APOBEC3s and mitochondrial DNA hypermutation in nasopharyngeal cancer
por: Wakae, Kousho, et al.
Publicado: (2020)

Serum EBV antibodies and LMP-1 in Polish patients with oropharyngeal and laryngeal cancer
por: Fołtyn, Sylwia, et al.
Publicado: (2017)

The EBV-encoded Latent Membrane Proteins, LMP2A and LMP2B, Limit the Actions of Interferon by Targeting Interferon Receptors for Degradation
por: Shah, Khilan M., et al.
Publicado: (2009)

A Therapeutic Approach to Nasopharyngeal Carcinomas by DNAzymes Targeting EBV LMP-1 Gene
por: Yang, Lifang, et al.
Publicado: (2010)

The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy
por: Lo, Angela Kwok-Fung, et al.
Publicado: (2021)

EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter
por: Shi, Feng, et al.
Publicado: (2019)

Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance
por: Xie, Longlong, et al.
Publicado: (2020)

EBV-LMP1 promotes radioresistance by inducing protective autophagy through BNIP3 in nasopharyngeal carcinoma
por: Xu, San, et al.
Publicado: (2021)

Conformational change of adenine nucleotide translocase‐1 mediates cisplatin resistance induced by EBV‐LMP1
por: Zhao, Lin, et al.
Publicado: (2021)

Down-Regulation of EBV-LMP1 Radio-Sensitizes Nasal Pharyngeal Carcinoma Cells via NF-κB Regulated ATM Expression
por: Ma, Xiaoqian, et al.
Publicado: (2011)

Downregulation of ATOH8 induced by EBV-encoded LMP1 contributes to the malignant phenotype of nasopharyngeal carcinoma
por: Wang, Zifeng, et al.
Publicado: (2016)

Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
por: Zhang, Chaoting, et al.
Publicado: (2021)

Analysis of EBNA-1 and LMP-1 variants in diseases associated with EBV infection in Chinese children
por: Ai, Junhong, et al.
Publicado: (2012)

Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma
por: Zhu, Shanli, et al.
Publicado: (2020)

LMP1-EBV Gene Deletion Mutations and HLA Genotypes of Nasopharyngeal Cancer Patients in Vietnam
por: Trinh, Cua Thi Hong, et al.
Publicado: (2023)

Correction: Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance
por: Xie, Longlong, et al.
Publicado: (2022)

Identification and characterization of novel B-cell epitopes within EBV latent membrane protein 2 (LMP2)
por: Xue, Xiangyang, et al.
Publicado: (2011)

Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs
por: Cho, Seok-Goo, et al.
Publicado: (2015)

Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy
por: Hu, Jianmin, et al.
Publicado: (2020)

Positive regulation of TAZ expression by EBV-LMP1 contributes to cell proliferation and epithelial-mesenchymal transition in nasopharyngeal carcinoma
por: He, Jiang, et al.
Publicado: (2016)

(−)-Epigallocatechin-3-Gallate Inhibits EBV Lytic Replication via Targeting LMP1-Mediated MAPK Signal Axes
por: Li, Hongde, et al.
Publicado: (2021)

Analysis of a structured intronic region of the LMP2 pre-mRNA from EBV reveals associations with human regulatory proteins and nuclear actin
por: Kumarasinghe, Nuwanthika, et al.
Publicado: (2019)

Genetic variability and mutation of Epstein‒Barr virus (EBV)-encoded LMP-1 and BHRF-1 genes in EBV-infected patients: identification of precise targets for development of personalized EBV vaccines
por: Wang, Yue, et al.
Publicado: (2023)

Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy: Erratum
por: Hu, Jianmin, et al.
Publicado: (2022)

Identification of a novel variant of LMP-1 of EBV in patients with endemic Burkitt lymphoma in western Kenya
por: Wohlford, Eric M, et al.
Publicado: (2013)

B1.12: a novel peptide interacting with the extracellular loop of the EBV oncoprotein LMP1
por: Ammous-Boukhris, Nihel, et al.
Publicado: (2019)

LMP1 and Dynamic Progressive Telomere Dysfunction: A Major Culprit in EBV-Associated Hodgkin’s Lymphoma
por: Knecht, Hans, et al.
Publicado: (2017)

The EBV-Encoded Oncoprotein, LMP1, Recruits and Transforms Fibroblasts via an ERK-MAPK-Dependent Mechanism
por: Davis, Alexandra M, et al.
Publicado: (2021)

Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma
por: Yuan, Qi, et al.
Publicado: (2023)

PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vajr3dd17ctuvuqhshktfujdi9